Leaderboard
Anzeige
medline.ch
En
|
De
Impressum
No articles selected!
View Cart
You are here:
Oncology
»
Urologic Neoplasms
25. August 2026
Search
medline.ch
Urologic Neoplasms
Advanced search
Dermatology
Endocrinology
Nutrition
Gastroenterology
Gynecology
Haematology
Infectious diseases
Cardiovascular Diseases
Musculoskeletal Diseases
Neurology
Oncology
Musculoskeletal System
Blood
Endocrine System
Gynecologic Neoplasms
Skin
Gastrointestinal
ORL
Respiratory Tract
Urologic Neoplasms
CNS
ORL
Pediatrics
Psychiatry
Respiratory Tract
Sports
Urology-Nephrology
Rect Top
Anzeige
Zoom:
Page 1 of 9047
Articles 1 - 20 / 180934
A rule-based, feedback-driven framework for fully automated prostate VMAT planning.
J Appl Clin Med Phys
Sangster J, Taylor M, Jolly D, Gastaldo J, Lorenz F.
PMID: 42638300 [PubMed - indexed for MEDLINE]
Clinical impact of routine second‑opinion reading of [¹⁸F]FDG‑PET/CT in newly diagnosed invasive bladder cancer: A multicentre study in a centralised referral network.
Eur J Nucl Med Mol Imaging
Lijnen RAG, Vierling ML, Ringia JB, Hendricksen K, KleinJan GH, Postema AW, Vogel WV, Boellaard TN, Braat AJAT, Heijmen L, van Rhijn BWG, Mertens LS.
PMID: 42637974 [PubMed - as supplied by publisher]
Metallic versus polymeric ureteric stents for chronic malignant ureteric obstruction: a systematic review and meta-analysis.
World J Urol
Lim QY, Kyaw L, Ong CSH, Law YXT, Tiong HY.
PMID: 42637852 [PubMed - indexed for MEDLINE]
Post-translational modifications in prostate cancer: coordinated oncogenic networks and clinical implications.
Biochim Biophys Acta Rev Cancer
Ren H, Li X, Jiang Z, Bai Y, Ai J.
PMID: 42637058 [PubMed - as supplied by publisher]
High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial.
Lancet Oncol
Hennequin C, Sargos P, Roca L, Silva M, Latorzeff I, Peiffert D, Cozzi S, Benyoucef A, Hasbini A, Supiot S, Ronchin P, Wachter T, Azria D, Magne N, Zibouche M, Vial N, Cormier L.
PMID: 42636837 [PubMed - indexed for MEDLINE]
Nomograms for Predicting Recurrence and Oncologic Outcomes After Partial Nephrectomy for Renal Cell Carcinoma.
Clin Genitourin Cancer
Menezes Jesus VL, Dos Anjos GC, Alves GKJ, Sandoval EAA, Barros GG, Cho DH, Lima FVS, de Carvalho PA, Gallucci FP, Cardili L, Pontes J Junior, Nahas WC, Cordeiro MD.
PMID: 42636730 [PubMed - as supplied by publisher]
Interconnectedness of Factors Affecting Patient Willingness to Discuss Prostate Cancer Clinical Trials With Physicians.
JCO Oncol Pract
Liyanage JSS, Ong V, Hamel LM, Eggly S, Carducci MA, Lansey DG, Heath EI, Moore TF, Albrecht TL, Manning MA, Kim S.
PMID: 42636423 [PubMed - as supplied by publisher]
Randomized trial of adjuvant 5-FU-platinum vs paclitaxel-platinum for high-risk penile cancer.
J Natl Cancer Inst
Noronha V, Menon N, Shah M, Patil V, Dhanawat A, Prakash G, Pal M, Arora A, Misra A, Goud S, More S, Yadav A, Murthy V, Maitre P, Menon S, Popat P, Sable N, Agarwal A, Rangarajan V, Shetake A, Badwe R, Prabhash K.
PMID: 42636270 [PubMed - as supplied by publisher]
A Phase 2 Study of Berzosertib in Combination with Carboplatin compared to Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer.
Cancer Res Commun
Choudhury AD, Zhong C, Xie W, Kochupurakkal BS, Wu PI, Riaz IB, Liu R, Yang DD, Folefac E, Lee D, Parikh M, Einstein DJ, Kessler ER, Mayer T, McKay RR, Pace A, Mouw KW, Chen L, Adalsteinsson VA, Van Allen EM, Kunos CA, Gore SD, Das B, D'Andrea A, Taplin ME, Shapiro GI.
PMID: 42636061 [PubMed - as supplied by publisher]
A single-center study of prognostic impact and treatment implications of cribriform pattern in prostate cancer.
Discov Oncol
Handke A, Dellino M, Orf C, Wang N, Darr C, Bach P, Roghmann F, Tully KH.
PMID: 42635876 [PubMed]
Multimodal artificial intelligence in prostate cancer: integrating multiparametric MRI with clinicopathological, molecular, and functional imaging data.
Abdom Radiol (NY)
Fujiwara M, Yoshida S, Banerjee I, Arita Y, Fujii Y.
PMID: 42635792 [PubMed - as supplied by publisher]
Outcomes of [(177)Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide in metastatic castration-resistant prostate cancer: a single-center retrospective study.
Eur J Nucl Med Mol Imaging
Arslan DF, Civan C, Sanli MO, Has Simsek D, Ekenel M, Basaran M, Erdem S, Ozcan F, Kuyumcu S, Sanli Y.
PMID: 42635771 [PubMed - as supplied by publisher]
Individual and composite socioeconomic inequalities in diagnosis, treatment, and survival of kidney cancer: a population-based analysis of the SEER database.
World J Urol
Zhang S, Sheng Y, Wang Y, Zhu S, Xiong H.
PMID: 42635662 [PubMed - indexed for MEDLINE]
Patient and primary care clinician perspectives on polygenic risk scores for prostate cancer screening: a national qualitative study.
Genet Med
Clayman ML, Cheam L, Gillespie C, Antwi AA, Anderson E, Danowski ME, Brunette CA, Song V, Grant CE, Scheuner MT, Wiener RS, Vassy JL.
PMID: 42635031 [PubMed - as supplied by publisher]
DYNAMIC ANDROGEN RESPONSE INDEX AND ITS ASSOCIATION WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY FOLLOWING NEOADJUVANT ANDROGEN DEPRIVATION THERAPY.
Exp Oncol
Afanasiev Y, Vozianov S, Danylets R, Grygorenko V, Shulyak O, Sosnin M, Kholokharenko I.
PMID: 42634840 [PubMed - indexed for MEDLINE]
The Synergistic Role of Phenolic Compounds in Docetaxel Chemoresistance in Prostate Cancer: A Systematic Review and Meta-Analysis.
Curr Pharm Des
Tatiparthi R, Aljabali AAA, Mishra Y, Mishra V.
PMID: 42634543 [PubMed - as supplied by publisher]
Editorial Comment on Exploratory Time-Dependent Patterns in Estimated Treatment Effect of Talazoparib Plus Enzalutamide in HRR Non-Deficient or Unknown Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the TALAPRO-2 Trial.
Int J Urol
Utsumi T.
PMID: 42634253 [PubMed - in process]
Diet and risk of bladder cancer: a systematic review of epidemiological evidence.
BJU Int
Miyajima K, Miszczyk M, Roessler N, Inoue S, Rajwa P, Matsukawa A, Urabe F, Mori K, Yanagisawa T, Karakiewicz PI, Teoh JY, Briganti A, Yang L, Schernhammer E, Kimura T, Shariat SF.
PMID: 42634248 [PubMed - as supplied by publisher]
Skin Rash Management Based on Early Elevation in the Eosinophil Proportion Within 3 Months of Initiating Apalutamide for Prostate Cancer.
Cancer Rep (Hoboken)
Koguchi D, Tsumura H, Tabata KI, Satoh T, Tachibana T, Hirano S, Ikeda M, Ishii D, Matsumoto K.
PMID: 42634213 [PubMed - indexed for MEDLINE]
Early patient-reported outcomes and decisional regret after robot-assisted radical prostatectomy: A prospective single-center cohort study.
J Robot Surg
Roh Y, Shin D, Park YH, Cho HJ, Ha US, Hong SH, Lee JY, Bang S.
PMID: 42634057 [PubMed - indexed for MEDLINE]
Articles 1 - 20 / 180934
Page 1 of 9047
Rect Bottom
Anzeige
Adserver Footer
Time frame
--unlimited--
1 Week
1 Month
3 Months
6 Months
1 Year
2 Years
3 Years
5 Years
10 Years
Sky right 1
Anzeige
Mediscope AG E-mail:
info@mediscope.ch
Disclaimer
|
Privacy Policy